PN-943Gut-directed integrin antagonist
PN-943 targets α4β7 integrin, a protein involved in directing immune cells towards the intestine. Early human work supports target engagement; that is different from proving remission in ulcerative colitis.
What is PN-943?
PN-943 is an oral peptide antagonist of α4β7 integrin, developed for intestinal inflammatory disease with limited systemic exposure.
How it works
It targets immune-cell trafficking into the gut. Receptor occupancy measures target engagement rather than disease remission.
Effects studied
Target engagement in humans
The checked publication describes pharmacokinetics and receptor occupancy in healthy volunteers. 1
Evidence: Early human pharmacology; healthy-volunteer findings cannot demonstrate ulcerative-colitis remission.
What does the evidence show?
Healthy-volunteer pharmacology study checked; efficacy not established by that study
Changing where immune cells travel
Inflammatory bowel disease involves more than excess acid or a sensitive stomach. One treatment strategy alters immune-cell trafficking into the gut. PN-943 is an oral peptide antagonist of α4β7 integrin, developed to influence this process while limiting systemic exposure.
What the early human work measured
The checked publication describes studies in healthy volunteers, including pharmacokinetics and receptor occupancy. These measurements ask how the compound behaves and whether it engages its intended target. They provide a reason to investigate clinical benefit, but participants without ulcerative colitis cannot demonstrate remission of that disease. 1
A name correction that changes the evidence
The archived source linked a PTG-100 study as evidence for PN-943, although the publications identify them as different compounds. PTG-100’s ulcerative-colitis findings cannot be attributed to PN-943. This correction matters because otherwise the profile would appear to have clinical evidence belonging to another molecule. 2
What a patient-focused result would need
A trial in ulcerative colitis would need to compare symptoms, endoscopic inflammation, sustained remission and adverse effects against an appropriate comparator. Low systemic exposure alone does not establish safety or effectiveness. The unresolved question is whether intestinal targeting improves disease control with an acceptable treatment burden.
Safety & status
Low systemic exposure does not by itself establish safety. Clinical assessment needs disease outcomes and adverse-effect follow-up with the actual preparation.
Country and product status
Country-specific product availability and authorisation require a separate current check.
Frequently asked questions
Is PN-943 the same compound as PTG-100?
No. The archived material misattributed a PTG-100 study to PN-943; those clinical findings must remain separate. 2 3
Does receptor occupancy mean colitis improves?
No. It shows engagement of the intended target; symptoms, endoscopic inflammation and sustained remission require clinical testing. 1
Sources
This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.
- PN-943 · Healthy-volunteer pharmacokinetic and pharmacodynamic study Primary pharmacology study · Primary trial abstract checked 27 October 2026; full paper and supplementary data not independently reviewed.
- PTG-100 · Separate-compound ulcerative colitis study Identity cross-check · Primary trial abstract checked 27 October 2026; full paper and supplementary data not independently reviewed.
- PTG-100 · archived reference misattributed to PN-943 Archive research lead · Retained archive DOI refers to PTG-100, a separate compound; identity cross-checked through PubMed 34474038. Not evidence of PN-943 efficacy.
Research provenance
This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.